SIG:ASXSigma Healthcare Ltd Analysis

Sigma Healthcare is trading around AUD 2.85, just above its 20‑day SMA of 2.85 but below the 200‑day SMA of 2.91, indicating a short‑term price plateau. Technical signals are mixed: the RSI sits at 53 (neutral), while the MACD histogram is negative and the MACD signal is flagged bearish, suggesting limited upside in the immediate horizon. Volume remains stable and the beta of 0.27 points to low market‑wide volatility, yet the 30‑day price swing of roughly 17.6% reflects moderate price turbulence.
Fundamentally, the stock appears markedly overvalued – a trailing P/E of 57 more than double the industry average of 27.6, and a DCF‑derived fair value of only 0.89 versus the current price. Revenue is soaring with a growth rate of over 180%, driven by strong Chemist Warehouse sales and an announced expansion into the UK and New Zealand. However, margins are thin, free cash flow is zero, and the dividend payout ratio is effectively nil, raising concerns about the sustainability of the modest 1.4% yield. Analyst consensus remains bullish with a median target of 3.30, implying roughly a 16% upside, but the valuation gap and dividend uncertainty temper long‑run enthusiasm.